CytomX Expands Licensing Agreement With Regeneron Pharmaceuticals
CytomX Therapeutics announced an expanded collaboration and licensing agreement with Regeneron Pharmaceuticals valued up to $4 billion, leading to a rise in CytomX's stock price. The deal builds on their initial partnership from 2022.
Topics: biotech collaboration licensing agreement pharmaceuticals